Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

EpiCept's first Ceplene commercial shipment to the EU triggers $2M milestone payment from Meda

EpiCept Corporation today announced that it has earned a $2 million milestone payment from Meda AB, for the first commercial shipment of Ceplene® (histamine dihydrochloride) to a major country in the European Union, as defined in the agreement.

4 May 2010

Broccoli component sulforaphane targets and kills breast cancer stem cells

A compound derived from broccoli could help prevent or treat breast cancer by targeting cancer stem cells -- the small number of cells that fuel a tumor's growth -- according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

4 May 2010

Par Pharmaceutical signs exclusive licensing agreement with Glenmark to market ezetimibe in the U.S.

Par Pharmaceutical Companies, Inc. today announced that its generic division, Par Pharmaceutical, has entered into an exclusive licensing agreement with Glenmark Generics Limited and Glenmark Generics Inc., USA to market ezetimibe 10 mg tablets, the generic version of Merck & Co. Inc.'s Zetia, in the U.S. Zetia is a cholesterol modifying agent with annual U.S. sales of approximately $1.4 billion, according to IMS Health data.

4 May 2010

TB Alliance, AstraZeneca sign research collaboration agreement to develop drugs against tuberculosis

The Global Alliance for TB Drug Development and AstraZeneca announced today at the 2010 BIO International Convention that they have entered into a research collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis, including drug resistant strains of the disease.

4 May 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2010.

4 May 2010

FDA issues advisory on prostate cancer drugs

Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.

3 May 2010

HTG, JWCI collaborate to develop new approaches for early stage primary cutaneous melanoma diagnosis

HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™), today announced it signed a collaboration agreement with the John Wayne Cancer Institute (JWCI) at Saint John's Health Center in Santa Monica, California. Under the terms of the agreement, HTG and JWCI (Department of Molecular Oncology, Dave S. B. Hoon, Ph.D., Director) will collaborate to generate a novel mRNA signature that can measure the gene expression differences in melanoma and benign nevi using HTG's qNPA technology in classical surgical pathology samples.

3 May 2010

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced interim study results that showed its doxorubicin prodrug INNO-206 demonstrated statistically significant anti-tumor activity in human myeloma tumor cells growing in immune-deficient mice compared to a control group, while exhibiting significantly less toxicity than doxorubicin even though INNO-206 was administered at much higher doses.

3 May 2010

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced an amendment to its 2005 collaboration agreement with AstraZeneca expanding the TC-5619 development program. In addition to the current development of TC-5619 in cognitive dysfunction in schizophrenia (CDS), the amended terms provide for parallel development in attention deficit/hyperactivity disorder (ADHD) and potentially Alzheimer's disease.

3 May 2010

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

3 May 2010

Ethicon Endo-Surgery SEDASYS CAPS system receives European Union CE Mark, Health Canada approval

Ethicon Endo-Surgery today announced that the SEDASYS® System, the first computer-assisted personalized sedation (CAPS) system, was granted a CE Mark for the European Union for routine colonoscopy and screening of the upper gastrointestinal tract (EGD procedures), and Health Canada granted regulatory approval for the SEDASYS® System for use by healthcare professional teams during routine colonoscopy.

3 May 2010

Investment report on Spectrum Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Spectrum Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

3 May 2010

Protein test to determine response of lung cancer patients to erlotinib

Testing for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, especially when other testing methods are unavailable, according to new data presented at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

3 May 2010

Triple combination therapy with OM, AML, HCTZ more effective at lowering blood pressure

Results of a new study found that the investigational triple combination therapy of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) demonstrated significantly greater mean reductions at week 12 in blood pressure (37.1/21.8 mm Hg versus 27.5 to 30.0/15.1-18.0 mm Hg LS Mean Reductions, P< 0.0001), as compared to corresponding dual combination therapy (dual components).

3 May 2010

Sistemic announces availability new SistemRNA Technology

Sistemic today announced immediate availability new SistemRNA product lines in key therapeutic areas including oncology and inflammation. These new product additions will strengthen strategic decision making at critical stages of the drug discovery and development process, helping to realise the full value of client's compound assets.

3 May 2010

Celgene seeks court declaration over claims of romidepsin injection usage for T-cell lymphomas

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it received a complaint filed by Celgene Corporation seeking a declaration from the court that four Cyclacel-owned patents, which claim the use of romidepsin injection in T-cell lymphomas, are not infringed by Celgene's products and are invalid.

3 May 2010

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

Monitoring of cell viability and toxicity are critical to many areas of biological and biomedical research. This is true for understanding the molecular and biochemical pathways regulating cell viability, for developing therapeutic agents which modulate cell viability and for identifying potential cytotoxic side effects of potential therapeutic agents.

3 May 2010

PEAK Surgical announces positive results from two PRECISE Clinical Studies for breast cancer diagnosis

PEAK Surgical, Inc. today announced positive results from two of its ongoing PRECISE Clinical Studies (Pulsed Plasma Radiofrequency to ReduCe Thermal Injury and Improve Surgical HEaling) demonstrating the clinical benefits of using the PEAK PlasmaBlade® tissue dissection device during lumpectomy for the diagnosis of breast cancer. The study findings were presented at the 11th Annual Meeting of the American Society of Breast Surgeons (ASBS) in poster sessions.

3 May 2010

ExacTrac SV system allows precise targeting of radiotherapy using real-time X-ray images

A system that allows precise targeting of radiotherapy using real-time X-ray images has allowed French doctors to increase the dose of radiation they administered to lung and liver cancers while minimizing harm to nearby healthy tissue, researchers report at the 2nd European Lung Cancer Conference.

3 May 2010

Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials

Advaxis, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is advancing the clinical development of its lead prostate cancer immunotherapeutic toward clinical trials.

3 May 2010

Oncology News and Research

Further Reading

EpiCept's first Ceplene commercial shipment to the EU triggers $2M milestone payment from Meda

Broccoli component sulforaphane targets and kills breast cancer stem cells

Par Pharmaceutical signs exclusive licensing agreement with Glenmark to market ezetimibe in the U.S.

TB Alliance, AstraZeneca sign research collaboration agreement to develop drugs against tuberculosis

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

FDA issues advisory on prostate cancer drugs

HTG, JWCI collaborate to develop new approaches for early stage primary cutaneous melanoma diagnosis

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

Ethicon Endo-Surgery SEDASYS CAPS system receives European Union CE Mark, Health Canada approval

Investment report on Spectrum Pharmaceuticals

Protein test to determine response of lung cancer patients to erlotinib

Triple combination therapy with OM, AML, HCTZ more effective at lowering blood pressure

Sistemic announces availability new SistemRNA Technology

Celgene seeks court declaration over claims of romidepsin injection usage for T-cell lymphomas

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

PEAK Surgical announces positive results from two PRECISE Clinical Studies for breast cancer diagnosis

ExacTrac SV system allows precise targeting of radiotherapy using real-time X-ray images

Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials

Cancer Research eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News